1Kaplan MM, Gershwin ME. Primary biliary cirrhosis [ J]. N Engl J Med, 2005, 353 (12): 1261 -1273.
2Kouroumalis E. Pathogenesis of PBC [ J ]. World J Gastroenterol, 2006, 12 (15) : 2320-2327.
3Amano K, Leung PS, Rieger R, et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food addictive, 2 octynoic acid [ J]. J Immunol,2005, 174 (9): 5874-5883.
4Heathcote EJ, Cauch Dudek K, Walker V, et al. The Canadian multicenter double - blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis [ J ]. Hepatology,1994, 19 (5): 1149-1156.
5Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis [ M/CD]. The Cochrane Database of Systematic Revlews 2001, Issue4. Art. No. CD000551. DOI: 10. 1002/14651858. CD000551.
6Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis [J]. Gastroenterology, 2005, 128 (2): 297-303.
7Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTC) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis [J]. Hepatology, 2005, 42 (5) : 1184 -1193.
8Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three - year randomized trial [ J ]. Hepatology,2005, 41 (4): 747-752,
9Prince M, Chrlstensen E, Gluud C. Glueoeorticosteroids for primary biliary cirrhosis [ M/CD]. The Cochrane Database of Systematic Reviews 2005 Issue 2.
